Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of [225Ac]Ac-A9-3408 in Subjects With Unresectable or Metastatic Melanoma

NCT07076550 is registered in ClinicalTrials.gov with Alpha-9 Oncology USA Inc. as lead sponsor.

NCT NCT07076550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07076550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of [225Ac]Ac-A9-3408 in Subjects With Unresectable or Metastatic Melanoma
Lead sponsor
Alpha-9 Oncology USA Inc.
Phase
Phase 1
Overall status
Terminated
Start date
November 19, 2025
Completion date
July 9, 2026
Enrollment
5 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma metastatic, mucosal melanoma, uveal melanoma, metastatic